Case Report: Individualized circulating tumor DNA monitoring guides olaparib adjuvant therapy: an early-stage breast cancer case with somatic BRCA2 mutation

Key Points

• Circulating tumor DNA monitoring effectively guides olaparib therapy in early-stage breast cancer.
• The patient's somatic BRCA2 mutation indicates a likely responsiveness to olaparib treatment.
• Personalized treatment strategies improve outcomes for patients with triple-negative breast cancer.
• Observational case analysis showcases benefits of tailored therapy using molecular biomarkers.

Abstract